Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MSD Seeks Lung Cancer Indication for Pembrolizumab in Japan
March 1, 2016
- Shionogi Links Arms with Roche on Sakigake-Designated Anti-Flu Drug
March 1, 2016
- New Presidents Announced for Alfresa, Suzuken, Fuji Pharma
February 29, 2016
- Takeda Gets Approval for Blister Packs Containing Takecab for H. pylori Eradication
February 29, 2016
- Novartis Seeks Japan Approval of Malaria Drug
February 29, 2016
- GSK, Daiichi Sankyo Voluntarily Recalling Zyrtec Tablets 5
February 29, 2016
- PCSK9 Inhibitor Repatha Expected to Debut this Spring, with Competing Products to Follow
February 29, 2016
- Daiichi Sankyo Launches Japan Clinical Trial on DMD Nucleic Acid Therapy
February 26, 2016
- Sanofi Seeks to Change Lyxumia Indication to Type 2 Diabetes without Strings
February 26, 2016
- Daiichi Sankyo to Revamp Organization to Boost Cancer R&D
February 26, 2016
- Torii to Expand Sales Force to 570 by FY2018; Will Actively Seek Acquisitions, Alliances
February 26, 2016
- Astellas Seeks Japan Approval of IBS-C Treatment Linaclotide
February 25, 2016
- Mitsubishi Tanabe’s New US Unit to Explore M&A Opportunities in Its Field of Specialty
February 25, 2016
- Takeda, ASKA Announce Deal on Ecard Authorized Generic
February 25, 2016
- Rohto Aims to Enter Field of Regenerative Medicine by 2020, with Initial Focus on Fibrotic Diseases
February 25, 2016
- Kyorin Holdings to Shutter Nagano Plant in September
February 24, 2016
- Kipres AG Certain to Hit Shelves before Rivals as Reimbursement Request Filed
February 24, 2016
- Osteoporosis Drug Romosozumab Delivers Positive PIII Data: Amgen Astellas
February 24, 2016
- AZ Initiates Voluntary Recall of Pulmicort Turbuhaler in Japan
February 24, 2016
- PeptiDream, JCR to Collaborate to Discover Peptide-Drug Conjugates that Pass Through Blood-Brain Barrier
February 24, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…